Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal ... (be the leader in the development and com...)

Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics

Date:5/5/2008

be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM) for the reduction of pain associated with venous access procedures. The second product in the pipeline, Adlea, has been shown to reduce pain after only a single administration for weeks to months in multiple settings based on mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

(1) Zempsky WT, Bean-Lijewski J, Kauffman RE et al. Needlefree Powder

Lidocaine Delivery System Provides Rapid Effective Analgesia for

Venipuncture or Cannulation Pain in Children: Randomized,

Double-Blind Comparison of Venipuncture and Venous Cannulation Pain

After Fast-Onset Needlefree Powder Lidocaine or Placebo Treatment

Trial. Pediatrics. 2008;121(5):1-9.

(2) Anesiva, Data on File.

(3) Wong DL and Baker CM. Pain in Children: Comparison of Assessment

Scales. Pediatric Nursing. 1988;14:9-17.

(4) Fradet C, McGrath PJ, Kay J, Adams S, Luke B. A prospective survey

of reactions to blood tests by children and adolescents. Pain.

1990;40:53-60.

(5) American Academy of Pediatrics Committee on Psychosocial Aspects of

Child and Family Health and American Pain Society Task Force on Pain

in Infants, Children, and Adolescents. The assessment and management

of acute pain in infants, children, and adolescents. Pediatrics.

2001;108:793-797.

(6) Bhargava R, Young K. Procedural pain management patterns in academic

pediatric emergency d
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
2. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
3. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
7. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
8. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
10. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
11. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)

Post Your Comments:

Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal ...(be the leader in the development and com...),Health